Case Report: Propranolol increases the therapeutic response to temozolomide in a patient with metastatic paraganglioma [version 1; peer review: 2 approved]

• Published in: F1000 research 2017, Vol.6, p.2087-2087
• Main Authors: Díaz-Castellanos, Miguel-Angel, Gómez de las Heras, Karina Villar, Díaz-Redondo, Tamara, González-Flores, Encarnación, Albiñana, Virginia, Botella, Luisa-María
• Format: Article
• Language: English
• Subjects: Bone cancer; Bone tumors; Cancer; Case Report; Case reports; Chemotherapy; Clinical trials; Dehydrogenases; Deoxyribonucleic acid; DNA; Gastrointestinal cancer; Gene expression; Hypertension; Hypoxia; Kidney cancer; Melanoma; Metabolism; Metastases; Metastasis; Mutation; Neck; Neural crest; Neuro-Oncology; Neuroendocrine tumors; Pain; Paraganglioma; Patients; Pelvis; Pituitary; Propranolol; Radiation therapy; Temozolomide; Tumors
• ISSN: 2046-1402; 2046-1402
• DOI: 10.12688/f1000research.13185.1

This case report presents the clinical evolution and management of a patient with a hereditary paraganglioma syndrome. This disease is characterized by rare tumors of neural crest origin that are symmetrically distributed along the paravertebral axis from the base of the skull and neck to the pelvis. In addition, these patients may develop renal cancer, gastrointestinal stromal tumors, pituitary adenomas, and bone metastasis in some cases. To date no successful therapeutic treatment has been reported. Total resection with postoperative radiotherapy and chemotherapy have been advocated, especially for the multiple metastasis. Here we show how the combination of high doses of the beta blocker propranolol (3 mg/Kg/day) and the DNA intercalating agent, temozolomide, has been successful in the treatment of a SDHA metastatic paraganglioma.